stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) EPS (diluted)
Revolution Medicines, Inc.'s EPS (diluted) for fiscal 2025 was −$5.95, compared with −$3.58 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$9.11. Over the past ten years it has ranged from −$22.33 (fiscal 2019) to −$2.01 (fiscal 2020); the current reading is higher than 38% of that period. Revolution Medicines, Inc. ranks 488th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$5.95 | — |
| FY2024 | −$3.58 | — |
| FY2023 | −$3.86 | — |
| FY2022 | −$3.08 | — |
| FY2021 | −$2.57 | — |
| FY2020 | −$2.01 | — |
| FY2019 | −$22.33 | — |
| FY2018 | −$21.24 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.90 | — |
| Jun 2026 | −$3.06 | — |
| Mar 2026 | −$2.29 | — |
| Dec 2025 | −$1.86 | — |
| 27 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ARGX argenex SE compare | $28.66 |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $5.68 |
| INCY Incyte Corporation compare | $1.88 |
| RPRX Royalty Pharma PLC compare | $1.40 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| INSM Insmed, Inc. compare | −$2.82 |
| BNTX BioNTech SE Sponsored ADR compare | −$6.85 |
| RVMD Revolution Medicines, Inc. | −$9.11 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RVMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement